- HYD -

Skip to content

Home
About Us
- Director’s Greetings
- Company History
Research
Products
Contact
News

HYD

News

Possible New Strategy to Combat SARS-CoV-2 - HYD

New Strategy to Combat SARS-CoV-2

Onkológiai befektetői konferencia New Yorkban - HYD

Oncology Investors’ Conference

IV. Deutériumdepléció Konferencia - HYD

4th Congress on Deuterium Depletion

34th Euro-Global Summit on Cancer Therapy & Radiation Oncology - HYD

Gábor Somlyai’s lecture in London

A Preventa sikere Kínában - HYD

Preventa: Success in China

BIO-Europe Spring partnering konferencia - HYD

BIO-Europe Partnering Conference

Gábor Somlyai’s lecture in Frankfurt - HYD

Gábor Somlyai’s lecture in Frankfurt

Gábor Somlyai’s lecture in Washington - HYD

Gábor Somlyai’s visit to Washington

Gábor Somlyai’s visit to China - HYD

Gábor Somlyai’s visit to China

FuturAqua to invest HUF 400 mln in cancer research - HYD

FuturAqua to invest 400 mln

PREVENTA deuterium-depleted drinking water product line received a MagyarBrands award - HYD

PREVENTA MagyarBrands award

HYD Pharma Receives Ethical Approval for Phase 2 Clinical Trial Investigating the Anticancer Effect of Deuterium Depletion in CL - HYD

HYD Receives Ethical Approval

HYD Pharma Receives GMP Certification for Deuterium-Depleted Water (DDW) Production Facility - HYD

HYD Receives GMP Certification

Budapest Business Journal’s report on GMP certification of HYD’s facility - HYD

GMP certification of HYD’s facility

Interviews with university professors about deuterium depletion research - HYD

Interviews about deuterium depletion

Posts navigation

Home | About us | Research | Areas of indication | Products | Contact | NewsPrivacy Policy | info@hyd.hu

Active agent | Vetera DDW-25 | Prostate cancer | Breast cancer | Lung cancer | Pancreatic cancer | Other tumor types

© 2020, HYD LLC. for Cancer Research and Drug Development